NeoGenomics is a pure play cancer genetics laboratory that provides diagnostic testing services to oncologists, pathologists, and hospitals throughout the US. The company utilizes advanced technologies like cytogenetics, flow cytometry, FISH, and molecular testing to analyze cancer samples. Key growth drivers include the aging US population which is increasing cancer incidence, and frequent discoveries linking new genes to cancer. NeoGenomics aims to accelerate its revenue growth and increase operating leverage through expanding its sales team, test offerings, and geographic reach.

1. NeoGenomics, Inc
OTCBB: NGNM
Time Matters. Results Count
Company Overview Presentation
October 2011

2. Forward-looking Statements
This presentation contains statements which constitute forward-looking
statements within the meaning of Section 27A of the Securities Act, as
amended; Section 21E of the Securities Exchange Act of 1934; and the
Private Securities Litigation Reform Act of 1995. The words “may”, “would”,
“could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”,
“goal”, and similar expressions and variations thereof are intended to
specifically identify forward-looking statements. All statements that are not
statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, and that actual results may differ materially
from those projected in the forward-looking statements as a result of
various factors. The risks that might cause such differences are identified
in our filings with the Securities and Exchange Commission. We undertake
no obligation to publicly update or revise the forward looking statements
made in this presentation to reflect events or circumstances after the date
of this presentation or to reflect the occurrence of unanticipated events.

3. NeoGenomics Laboratories
• Pure play cancer genetics laboratory testing
• Servicing: Oncologists, Pathologists and Hospitals throughout the U.S.
• Competitive through innovative products, advanced technologies and
outstanding service
• Rapidly growing Industry with tremendous market opportunity
• Accelerating revenue with increasing operating leverage
• 30% year over year revenue growth in Q3 11
• 40% of incremental $2.6 MM in revenue driven to bottom line in Q3

4. NeoGenomics’ Mission
To improve patient care through
exceptional cancer genetic
diagnostic services.

5. Management Team
• Douglas VanOort, Chairman & CEO
Operating Partner, Summer Street Capital Partners;
Chief Operating Officer, Quest Diagnostics, Inc.
• Robert Gasparini, Director & Chief Scientific Officer
Director of Genetics, U.S. Labs; Worldwide Marketing Mgr, Ventana Medical Systems
Asst. Director, Prenatal Diagnostic Center (Harvard)
• Steven Jones, Director & EVP - Finance
Chairman, Aspen Capital Group; Managing Member, Medical Venture Partners
Vice President, Merrill Lynch Investment Banking
• George Cardoza, Chief Financial Officer
CFO, Protocol Global Solutions
Controller, Central Region, Quest Diagnostics
• Robert Horel, Vice President, Sales & Marketing
Regional Manager, US Labs; Product Specialist, Ventana Medical Systems;
Pilot, United States Navy

6. Cancer Genetics Lab Testing (1)
• $5-6 billion market opportunity: “Personalized Medicine”
• Highest growth segment of lab Industry
• Approx. 360 Genetic Labs in the U.S.
• 2/3 affiliated with academic institutions
• Approx. 60 Commercial Labs perform 80% of testing
• 15-20 national/regional labs
• 12 other publicly-traded players
• High pace of industry consolidation
(1) Source: Washington G2 Reports

7. A Growing Landscape
VT
WA ME
MT
ND MI
MN NH
OR NY MA
ID
SD WI RI
WY MI PA
CT
IA NJ
NE OH
DE
IL IN
NV MD
WV
UT VA
CO
KS MO
CA KY
NC TN Facility
OK AR
SC 7k sq.ft.
AZ NM
AL GA
MS
LA
TX
CA Facility FL
18k sq.ft.
States sending specimens in 2010 FL Facility
31k sq.ft.

8. Advanced Technologies
Cytogenetics: chromosome analysis
“Neighborhood view from 1000 feet”
Flow Cytometry: cell surface marker analysis
“Single House view from 500 feet”
FISH: gene analysis
“Door and Window view”
Molecular testing: DNA sequence analysis
“View of serial number on door lock”

9. Key Customers
Pathologists and Hospital Path Groups: “Tech only”
• Enable community pathologists to compete with Large lab competitors
• Rapid Turnaround Time and Web based reporting
• Innovative technical component-only services – Flow, FISH, IHC
Oncologists and Clinician Groups: “Full Service”
• Specialized high level of service and outstanding quality
• Genetic Pathology Solutions™ (GPS) reporting – all relevant case data
on one page report

10. Key Growth Drivers
Industry
• Favorable demographics
• Increasing incidence of cancer as baby boomers age
• Frequent discoveries of new genes linked to cancer
Company Specific
• Flexible and powerful business model
• Solid pipeline of new diagnostic test offerings
• Expansion of sales team and geographic reach

11. Increasing Sales Force Productivity
77% of all Cancers Diagnosed are in People Age 55 or Older, the Fastest Growing
Segment of the US Population (American Cancer Society)
30.0%
25.0%
25.0%
20.2%
20.0%
15.0%
10.0%
5.6%
5.0% 3.2%
1.4%
0.0%
Under 55 55 to 64 65 to 74 75 to 84 85 and older
Percent Change in U.S. Population by Age: 2000 to 2005
(Source: U.S. Census Bureau)

12. Diagnostic Services and Cancer Markets
2011 New Male Cancer Cases 2011 New Female Cancer Cases
Prostate 240,890 (25%) Breast 230,480 (26%)
Lung & bronchus 115,060 (15%) Lung & bronchus 106,070 (14%)
Colon & rectum 71,850 10%) Colon & rectum 69,360 (10%)
Urinary bladder 52,070 (7%) Uterine corpus 46,470 (6%)
Lymphoma 40,880 (5%) Thyroid 36,550 (4%)
Melanoma (Invasive) 40,010 (5%) Lyphoma 34,310 (4%)
Kidney & renal pelvis 37,120 (4%) Melanoma (Invasive) 30,220 (4%)
Oral cavity & pharynx 27,710 (3%) Ovary 21,990 (3%)
Leukemia 25,320 (3%) Kidney & renal pelvis 23,800 (3%)
Pancreas 22,050 (3%) Leukemia 19,280 (3%)
All sites 822,300 (100%) All sites 774,370 (100%)
Total New Cases Estimated in 2011: 1,596,670
* Source: American Cancer Society, Cancer Facts 2011.

13. New Diagnostic Tests
Strategic Supply Agreement with Abbott Laboratories
• Allows NeoGenomics to develop and launch up to 3 Laboratory
Developed Tests (“LDTs”) using Abbott IP
• MelanoSITE - FISH-based test targeted at difficult to diagnose
Melanoma cases was first
• Launched in Q1 2010
• 84% Sensitivity and 98% Specificity
• 10 year agreement with two, 2 year renewals
• Transitions to FDA if Abbott obtains FDA approval
• Two additional LDTs for other cancers
• Test #2 targeted for Q4 2011 launch

14. Volume and Price Growth
22,000 $700
661 659 652
624 613 19,977
20,000 606 603 602 610
603 600 587
569 18,358 $600
552 567
18,000 534 523
522 572 570
493 504 509
479 484
16,000 449 15,396 $500
14,464 14,349
440 14,477
14,042
14,000
12,714
$400
12,000 11,316 11,188
10,457
10,000 9,490
8,383 $300
8,056
8,000 6,909
6,666
6,000 5,654 $200
4,482
4,196
4,000 3,475 3,377
2,664 3,309
$100
1,569
2,000 768
1,271
467
0 $0
Q1 05
Q2 05
Q3 05
Q4 05
Q1 06
Q2 06
Q3 06
Q4 06
Q1 07
Q2 07
Q3 07
Q4 07
Q1 08
Q2 08
Q3 08
Q4 08
Q1 09
Q2 09
Q3 09
Q4 09
Q1 10
Q2 10
Q3 10
Q4 10
Q1 11
Q2 11
Q3 11
Tests Completed Average Revenue/Test

15. Quarterly Revenue
$ 12,000 11,320
$ 11,000 10,466
$ 10,000
8,804
$ 9,000 8,708 8,755
8,418 8,490
7,799
7,297
$ 8,000 7,459
6,914
$ 7,000
5,920
$ 6,000 5,057
4,881
$ 5,000
4,163
3,795
$ 4,000
3,123
$ 3,000 2,344
2,243
1,763
1,602
$ 2,000 1,767
1,344
$ 1,000 559 751
230 345
$0
Q1 05
Q2 05
Q3 05
Q4 05
Q1 06
Q2 06
Q3 06
Q4 06
Q1 07
Q2 07
Q3 07
Q4 07
Q1 08
Q2 08
Q3 08
Q4 08
Q1 09
Q2 09
Q3 09
Q4 09
Q1 10
Q2 10
Q3 10
Q4 10
Q1 11
Q2 11
Q3 11
Quarterly Revenue ($, 000's)

16. Historical Financial Information
($, 000's) 2007 2008 2009 2010
Total Revenue $ 11,505 $ 20,015 $ 29,469 $ 34,371
% Growth 78.0% 74.0% 47.2% 16.6%
% Growth Adjusted * 70.0% 25.4%
Gross Margin % 52.0% 53.3% 51.6% 45.9%
Sales & Marketing as a % of Rev 20.5% 16.8% 23.4% 21.8%
General & Admin as a % of Rev 58.8% 40.9% 34.1% 32.8%
Total SG&A as a % of Rev 79.3% 57.7% 57.5% 54.5%
Net Income/(Loss) $ (3,380) $ (1,383) $ (2,243) $ (3,303)
Diluted EPS ($0.11) ($0.04) ($0.06) ($0.09)
Adjusted EBITDA $ (1,017) $ 809 $ (103) $ (566)
Summary Testing Metrics
% Growth in Tests Performed 63.7% 55.7% 39.7% 25.5%
% Growth - Adjusted* 57.0% 36.1%
* Excludes impacts from insourcing by one large acount (i.e., growth from all other customers).

17. Quarterly Financial Information
($, 000's) Q3 10 Q4 10 Q1 11 Q2 11 Q3 11
Total Revenue $ 8,708 $ 8,755 $ 8,805 $ 10,466 $ 11,320
% Growth (YoY) 19.3% 12.3% 4.6% 23.3% 30.0%
% Growth (YoY) - Adjusted* 23.9% 17.0% 11.4% 25.0% 32.0%
Gross Margin 44.7% 44.6% 43.9% 44.5% 44.8%
Sales & Marketing as a % of Rev 22.8% 20.4% 19.9% 16.1% 15.2%
General & Admin as a % of Rev 33.5% 30.6% 32.1% 29.5% 29.2%
SG&A Expenses 4,902 4,467 4,576 4,770 5,032
Total SG&A as a % of Rev 56.3% 51.0% 52.0% 45.6% 44.5%
Net Income/(Loss) $ (1,198) $ (377) $ (893) $ (293) $ (143)
Diluted EPS ($0.03) ($0.01) ($0.02) ($0.01) ($0.00)
Adjusted EBITDA $ (399) $ (97) $ 29 $ 483 $ 693
Summary Operating Data
% Growth in Tests Performed (YoY) 29.4% 12.9% 9.6% 26.9% 38.0%
% Growth (YoY) - Adjusted* 36.8% 19.5% 18.6% 32.0% 40.6%
* Excludes impacts from insourcing by one large acount and other non-recurring revenue/tests.

18. Key Financial Information
Recent Share Price (10/18/2011): $ 1.15
Basic Shares Outstanding: 42.8 M
Current Market Cap: $49.6 M
Treasury Stock Diluted Shares: ~45.0 M
Fully Diluted Shares: 50.7 M
Public Float Shares: 35.0 M
52 Week High/Low: $0.96/$1.67
Avg. Daily Trading Volume (3 Mos): 17,788

19. Historical Stock Price

20. NeoGenomics
• Emerging leader in the fastest growing segment of the lab testing industry
• Strong competitive advantages and new product portfolio
• Strong Management Team with directly relevant industry experience
• Accelerating profitability through revenue growth and increased operating
leverage
• Q4 2011 guidance of $11.4 - $12.0 MM of revenue with $0.00 - $0.01 per
share of net income